Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.

Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009 Jun; 8(6):1655-65.

View in: PubMed

subject areas

Animals
Antineoplastic Agents
Apoptosis
Cell Cycle
Cell Line, Tumor
Cell Proliferation
Cell Survival
Chromatography, Liquid
Dose-Response Relationship, Drug
Flow Cytometry
Humans
Magnetic Resonance Spectroscopy
Male
Mass Spectrometry
Mice
Mice, Inbred BALB C
Mice, Nude
Molecular Structure
Prostatic Neoplasms
Receptors, LHRH
Spectroscopy, Fourier Transform Infrared
Taxoids
Triptorelin Pamoate
Tumor Burden
Xenograft Model Antitumor Assays

authors with profiles

Udaya B. Kompella